Stay updated on scAAV9.U1a.hSGSH Gene Transfer Clinical Trial
Sign up to get notified when there's something new on the scAAV9.U1a.hSGSH Gene Transfer Clinical Trial page.

Latest updates to the scAAV9.U1a.hSGSH Gene Transfer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page has updated the details of a clinical trial for UX111, including the timeline for the administration of prophylactic immunomodulatory therapy, and has changed the contact email for a key individual involved in the trial.SummaryDifference2%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check42 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check56 days agoChange DetectedThe website has updated the status of the Phase I/II/III Gene Transfer Clinical Trial of ScAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA to 'Completed' and provided new contact information for trial recruitment, while removing previous details about the trial's active status and certain assessment metrics.SummaryDifference4%
- Check63 days agoChange DetectedThe study has shifted focus from evaluating the efficacy and safety of ABO-102 to UX111 for treating MPS IIIA, with significant updates including the introduction of adjuvant immunomodulatory therapy and detailed eligibility criteria for participants.SummaryDifference54%
- Check92 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to scAAV9.U1a.hSGSH Gene Transfer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the scAAV9.U1a.hSGSH Gene Transfer Clinical Trial page.